PRNP and Creutzfeldt Jacob disease: In 2018, another experimental treatment program was initiated at University College London Hospital on six patients diagnosed with CJD (five sporadic and one iatrogenic) to evaluate the tolerability and efficacy of a humanized monoclonal antibody, named PRN100 directed against PrPC, administered by intravenous administration (Mead et al., 2022).